Laurence L Greenhill Selected Research

Combined Modality Therapy

1/2020	Trajectories of Growth Associated With Long-Term Stimulant Medication in the Multimodal Treatment Study of Attention-Deficit/Hyperactivity Disorder.
1/2019	Editorial: Does a Diagnosis of Attention-Deficit/Hyperactivity Disorder in Childhood Determine an Increased Risk for Future Criminality?
6/2017	Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression.
1/2017	Distinct effects of childhood ADHD and cannabis use on brain functional architecture in young adults.
5/2015	Developmental progression to early adult binge drinking and marijuana use from worsening versus stable trajectories of adolescent attention deficit/hyperactivity disorder and delinquency.
3/2013	Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.
2/2012	Blood pressure and heart rate over 10 years in the multimodal treatment study of children with ADHD.
5/2009	The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.
5/2009	Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment.
8/2007	Secondary evaluations of MTA 36-month outcomes: propensity score and growth mixture model analyses.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Laurence L Greenhill Research Topics

Disease

54	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2020 - 03/2002
2	Substance-Related Disorders (Drug Abuse) 03/2013 - 08/2007
1	Pervasive Child Development Disorders 07/2015
1	Depressive Disorder (Melancholia) 10/2009
1	Major Depressive Disorder (Major Depressive Disorders) 10/2009
1	Drug-Related Side Effects and Adverse Reactions 09/2008
1	Headache (Headaches) 05/2006
1	Sleep Initiation and Maintenance Disorders (Insomnia) 05/2006
1	Weight Loss (Weight Reduction) 05/2006
1	Blindness (Hysterical Blindness) 02/2006
1	Anxiety Disorders (Anxiety Disorder) 02/2006
1	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2006
1	Conduct Disorder (Conduct Disorders) 01/2004

Drug/Important Bio-Agent (IBA)

16	Pemetrexed (MTA)FDA Link 01/2020 - 05/2002
14	Methylphenidate (Ritalin)FDA LinkGeneric 12/2016 - 03/2002
7	Atomoxetine Hydrochloride (Strattera)FDA LinkGeneric 12/2017 - 08/2006
3	Amphetamine (Amfetamine)FDA LinkGeneric 08/2006 - 06/2003
3	TabletsIBA 05/2006 - 01/2006
3	Modafinil (Provigil)FDA Link 05/2006 - 01/2006
3	AdderallIBA 10/2003 - 06/2003
2	Pharmaceutical PreparationsIBA 08/2006 - 01/2006
2	SLI381IBA 06/2003 - 06/2003
1	Antipsychotic Agents (Antipsychotics)IBA 07/2015
1	Norepinephrine Plasma Membrane Transport Proteins (Norepinephrine Transporter)IBA 04/2011
1	Antidepressive Agents (Antidepressants)IBA 10/2009
1	DNA (Deoxyribonucleic Acid)IBA 10/2007
1	Venlafaxine Hydrochloride (Effexor)FDA LinkGeneric 08/2007
1	Dexmethylphenidate Hydrochloride FDA LinkGeneric 07/2006
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 05/2006
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 02/2006
1	Fluvoxamine (Luvox)FDA LinkGeneric 02/2006
1	4,4'-dibenzamido-2,2'-stilbenedisulfonic acidIBA 01/2004
1	Delayed-Action PreparationsIBA 06/2003
1	SaltsIBA 06/2003

Therapy/Procedure

24	Combined Modality Therapy 01/2020 - 05/2002
3	Drug Therapy (Chemotherapy) 07/2015 - 01/2004
1	Aftercare (After-Treatment) 05/2009
1	Off-Label Use 09/2008
1	Therapeutics 01/2004